Comparison CompoundClassPathway / targetResearch focusFormat SemaxACTH-fragment peptideBDNF / NGF signallingNeurotrophic & cognitive researchVial SelankAnxiolytic peptide (Tuftsin analogue)GABA-BDNF interplayNeuropeptide / anxiolytic-model researchVial Semax + SelankPeptide blendCombined BDNF/NGF & GABA pathwaysComparative neuropeptide researchVial CerebrolysinMulti-peptide preparationNeurotrophic factor signallingNeurotrophic-pathway researchVial P21 (P021)Neurotrophic peptideTrkB receptorBDNF-mimetic signalling researchVial DihexaPeptidomimetic (small molecule)HGF / c-Met pathwaySynaptogenesis researchCapsules J-147Small moleculeMitochondrial / neurotrophic signallingNeuroprotective-model researchCapsules 9-Me-BCSmall molecule (beta-carboline)GDNF / dopaminergic pathwayNeurotrophic-model researchCapsules Methylene BlueSmall molecule (phenothiazine)Mitochondrial electron transport chainOxidative-stress & metabolism researchCapsules DSIPSleep-regulatory peptideDelta-wave / neuroendocrine axisSleep-signalling researchVial Every compound in this category is supplied as Research Use Only material with: Peer-reviewed literature underpinning this category
Yeo, K.-W
Consistently, cleaved caspase-3 expression was not increased under basal conditions (Figure S6B-D)
The researchers named it Delta Sleep-Inducing Peptide because of its ability to promote delta wave activity on EEG readings, the signature electrical pattern of deep, restorative sleep
All study participants were randomly assigned to an experimental treatment group that received subcutaneous injection of cagrilintide, once-weekly, in doses of either 0.3, 0.6, 1.2, 2.4, or 4.5 mg, as well as a one-daily 3.0 mg dose of liraglutide, and a volume matched placebo for control purposes
